Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
MacroGenics clinical trials
The registry lists 42 studies whose lead sponsor is MacroGenics. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 16, 2026.
Keep track of what changes. Save the MacroGenics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to MacroGenics.
- MacroGenics42 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 42 of 42.
- A Study of MGC030 in Participants With Advanced Solid TumorsNot yet recruitingNCT07822399Phase 1
- A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1
- A Study of Lorigerlimab in Participants With Advanced Solid TumorsRecruitingNCT06730347Phase 2
- A Study of MGC028 in Participants With Advanced Solid TumorsRecruitingNCT06723236Phase 1
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesActive, not recruitingNCT05362773Phase 1
- A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT05848011Phase 2
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedNCT05551117Phase 2
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
- Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1
- MGC018 With or Without MGA012 in Advanced Solid TumorsTerminatedNCT03729596Phase 1/2
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Phase 2/3
- A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral TherapyCompletedNCT05261191Phase 1
- Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerCompletedNCT02689284Phase 1/2
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerCompletedNCT02492711Phase 3
- Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerCompletedNCT01828021Phase 2
- MGD019 DART® Protein in Unresectable/Metastatic CancerCompletedNCT03761017Phase 1
- Safety Study of MGAH22 in HER2-positive CarcinomasCompletedNCT01148849Phase 1
- Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)TerminatedNCT02152956Phase 1/2
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedNCT03219268Phase 1
- Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusTerminatedNCT00920582Phase 3
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerTerminatedNCT04634825Phase 2
- The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusCompletedNCT00385697Phase 2/3
- Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic CancerTerminatedNCT00625586Phase 2
- Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)TerminatedNCT00870818Not applicable
- MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral TherapyCompletedNCT03570918Phase 1
- Flotetuzumab Expanded Access ProgramNo longer availableNCT04678466
- MGD009/MGA012 Combination in Relapsed/Refractory CancerCompletedNCT03406949Phase 1
- Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental ExposureNo longer availableNCT01206504
- RAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaCompletedNCT00101972Phase 1
- A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy AdultsCompletedNCT00515385Phase 1
- Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe PsoriasisTerminatedNCT00954915Phase 1/2
- Treatment of West Nile Virus With MGAWN1TerminatedNCT00927953Phase 2
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT04129320Phase 2/3
- Tissue Procurement Substudy for Participants in Study CP-MGA271-01TerminatedNCT01918930Phase 1
- Safety Study of MGD009 in B7-H3-expressing TumorsTerminatedNCT02628535Phase 1
- Subcutaneous Administration of Teplizumab in Adults With Type 1 DiabetesTerminatedNCT01189422Phase 1
- Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsCompletedNCT02982941Phase 1
- Phase 1 Study of MGD010 in Healthy SubjectsCompletedNCT02376036Phase 1
- Safety Study of MGA271 in Refractory CancerCompletedNCT01391143Phase 1
- Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1
- MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal CancerCompletedNCT03531632Phase 1/2
- Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal CarcinomaCompletedNCT02248805Phase 1